Safety, tolerability and pharmacokinetics and pharmacodynamics of HL2351, a novel hybrid fc-fused interleukin-1 receptor antagonist, in healthy subjects: A first-in-human study.
HL2351（一种新型混合型 fc 融合白细胞介素-1 受体拮抗剂）在健康受试者中的安全性、耐受性、药代动力学和药效学：首次人体研究
期刊:British Journal of Clinical Pharmacology
影响因子:3
doi:10.1111/bcp.14161
Oh Jaeseong, Huh Ki Young, Cho Young-Gyu, Cha Ji-Eun, Kim Se-Jin, Yoon Seo Hyun, Park Sung Sup, Yoon Hyunyee, Lee Jieon, Lee Howard
